Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72


Characteristics of accelerated disease in chronic myelogenous leukemia.

Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ.

Cancer. 1988 Apr 1;61(7):1441-6.


Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival.

Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, Hester JP, Bligham G, Gehan E, Freireich EJ.

Blood. 1985 Dec;66(6):1326-35.


Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia.

Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Smith TL, Talpaz M, Beran M, Cork A, Trujillo JM, Freireich EJ.

Cancer. 1986 Nov 1;58(9):2023-30.


Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease.

Terjanian T, Kantarjian H, Keating M, Talpaz M, McCredie K, Freireich EJ.

Cancer. 1987 Jan 15;59(2):297-300.


Chronic myeloid leukemia (CML): prognostic factors and survival analysis.

Braga GW, Chauffaille ML, Moncau JE, Souto EX, Silva MR, Kerbauy J.

Sao Paulo Med J. 1996 Jan-Feb;114(1):1083-90.


Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.

Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ.

Am J Med. 1987 Sep;83(3):445-54.


Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.

Derderian PM, Kantarjian HM, Talpaz M, O'Brien S, Cork A, Estey E, Pierce S, Keating M.

Am J Med. 1993 Jan;94(1):69-74.


Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.

Kantarjian HM, Shan J, Smith T, Talpaz M, Kozuch P, Rios MB, Cortes J, Giles FJ, O'Brien S.

Cancer. 2001 Nov 15;92(10):2501-7.


Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematologic observations, and identification of prognostic factors.

Castro-Malaspina H, Schaison G, Passe S, Pasquier A, Berger R, Bayle-Weisgerber C, Miller D, Seligmann M, Bernard J.

Cancer. 1984 Aug 15;54(4):675-86.


Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE.

Clin Cancer Res. 2002 Jul;8(7):2177-87.


Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia.

Kantarjian HM, Keating MJ, McCredie KB, Walters R, Talpaz M, Smith TL, Freireich EJ.

South Med J. 1987 Oct;80(10):1228-32.


Philadelphia chromosome-positive chronic myelocytic leukemia in children. Survival and prognostic factors.

Castro-Malaspina H, Schaison G, Briere J, Passe S, Briere J, Pasquier A, Tanzer J, Jacquillat C, Bernard J.

Cancer. 1983 Aug 15;52(4):721-7.


Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.

Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia.

Haematologica. 2008 Dec;93(12):1792-6. doi: 10.3324/haematol.13068. Epub 2008 Oct 6.


Prognostic features at diagnosis of chronic myelocytic leukemia.

Gomez GA, Sokal JE, Walsh D.

Cancer. 1981 May 15;47(10):2470-7.


Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.

Tavernier E, Le QH, Elhamri M, Thomas X.

Leuk Res. 2003 Mar;27(3):205-14.


Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.

Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM.

Blood. 2003 May 15;101(10):3794-800. Epub 2003 Jan 30.


Clinical investigation of human alpha interferon in chronic myelogenous leukemia.

Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J.

Blood. 1987 May;69(5):1280-8.


The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia.

Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ.

Cancer. 1987 May 15;59(10):1739-43.

Supplemental Content

Support Center